Psychedelic Research for Alcohol Use Disorder with Comorbid Major Depressive Disorder: An Unmet Need.
Current psychiatry reports – December 01, 2024
Source: PubMed
Summary
Promising breakthroughs in psychedelic medicine show that psilocybin and LSD may effectively treat both alcohol use disorder and major depressive disorder simultaneously. These conditions frequently occur together, making traditional treatments challenging. Studies reveal that psilocybin therapy significantly reduces drinking frequency and depressive symptoms, offering hope for a unified treatment approach.
Abstract
In this narrative review, we discuss evidence for psilocybin- and LSD-assisted treatment of alcohol use disorder (AUD) and major depressive disorder (MDD). We describe limitations of psychedelic research and posit methodological considerations when designing a trial in patients with both disorders. In AUD, a growing evidence base for psilocybin treatment shows a promising beneficial and sustained effect on measures of drinking frequency. In MDD, a recent meta-analysis has demonstrated that psilocybin therapy provides a large and consistent reduction in depressive symptoms compared to no treatment. Co-occurrence of MDD and AUD is quite prevalent, and this comorbidity exacerbates symptomatology of the two individual disorders and complicates their treatment. Theoretically, patients presenting with both AUD and MDD would benefit from an integrated therapy that could treat MDD and AUD simultaneously. We believe that more research into the efficacy of psilocybin in patients with both AUD and MDD is warranted and justified.